Exploring 3 High Growth Tech Stocks in the US Market

Over the last 7 days, the United States market has dropped 2.7%, yet it remains up by 23% over the past year, with earnings forecasted to grow by 17% annually. In this dynamic environment, identifying high growth tech stocks involves looking for companies that exhibit strong innovation potential and robust financial health to capitalize on future opportunities.

Top 10 High Growth Tech Companies In The United States

Click here to see the full list of 68 stocks from our US High Growth Tech and AI Stocks screener.

Let’s uncover some gems from our specialized screener.

Simply Wall St Growth Rating: ★★★★★☆

Overview: Digi Power X Inc. is an energy infrastructure company focused on developing data centers to support the growth of energy assets in the United States, with a market capitalization of $550.17 million.

Operations: Digi Power X generates revenue through colocation services ($15.41 million), cryptocurrency mining ($2.81 million), and sales of energy and electricity ($13.48 million). The company’s focus on developing data centers supports its diverse revenue streams in the energy sector.

Digi Power X, amidst a challenging financial backdrop with a net loss widening to $4.65 million from $1.63 million year-over-year and revenue dropping to $6.79 million from $9.28 million, is pivoting aggressively towards high-potential sectors within tech. The company recently inked a massive deal valued at up to $2.5 billion over its term with Cerebras Systems for an AI data center, underscoring its strategic shift towards specialized high-density AI infrastructure solutions—a market with burgeoning demand due to the exponential growth in AI applications. This move, coupled with its commitment to delivering state-of-the-art GPU services through a new agreement worth approximately $19.6 million, highlights Digi Power X’s focus on leveraging cutting-edge technology to foster significant future revenue streams despite current profitability challenges.

Simply Wall St Growth Rating: ★★★★★☆

Overview: Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing chimeric antigen receptor cell therapy for light chain amyloidosis and immune-mediated diseases, with a market cap of $553.44 million.

Operations: Immix Biopharma specializes in developing cell therapies targeting light chain amyloidosis and immune-mediated diseases, operating primarily in the United States and Australia. As a clinical-stage company, it does not currently generate revenue from product sales.

Immix Biopharma, showcasing a remarkable 56.6% annual revenue growth, is poised above the U.S. market average of 11.8%. Despite its current unprofitability, the company’s strategic focus on innovative CAR-T therapies for AL Amyloidosis signals potential for significant market impact, underscored by a recent complete response rate of 95% in phase trials and robust enrollment completion in NEXICART-2. With earnings projected to grow at 58.18% annually and recent successful $150 million equity offerings, Immix is strategically advancing towards profitability and expanding its influence in biotech through cutting-edge treatments and substantial R&D investments that align with growing healthcare demands.

Simply Wall St Growth Rating: ★★★★★☆

Overview: Annexon, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing medicines for treating inflammatory-related diseases, with a market cap of $866.73 million.

Operations: Annexon, Inc. is engaged in the discovery and development of treatments for inflammatory-related diseases. As a clinical-stage biopharmaceutical company, it currently does not generate revenue from product sales.

Annexon, despite its current unprofitability, is navigating a promising trajectory with expected earnings growth of 62.95% per year, significantly outpacing the industry average of 54.5%. The company’s aggressive focus on R&D, crucial for its long-term strategy in biotech innovation, is reflected in substantial investments that align well with its revenue growth forecast at an impressive rate of 60.7% annually. Recent participations in high-profile healthcare conferences and a strategic follow-on equity offering of $150 million underscore its proactive approach to fueling these ambitious growth plans.

Seize The Opportunity

Searching for a Fresh Perspective?

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com